GSTP1 rs1695: What Your Genotype Means

What each genotype means

Understanding the rs1695 Variant

The rs1695 variant, often referred to in scientific literature as the Ile105Val polymorphism, is a single nucleotide polymorphism (SNP) located on chromosome 11 at position 11q13.2. This specific change involves a substitution of a nucleotide that results in an amino acid change from isoleucine to valine at position 105 of the GSTP1 protein. Because this change occurs within the active site of the enzyme, researchers have long investigated whether it alters the protein's structural stability or its catalytic efficiency. As a common variant, it is found in a significant portion of the global population, making it a frequent subject of study in fields ranging from environmental toxicology to pharmacogenomics. By altering the amino acid sequence, this SNP may influence how effectively the GSTP1 enzyme performs its role in neutralizing potentially harmful substances within the cell.

The Role of the GSTP1 Gene

The GSTP1 gene provides instructions for creating the glutathione S-transferase pi 1 enzyme. This enzyme belongs to a larger family of glutathione S-transferases, which are essential for the body's detoxification processes. These enzymes function by catalyzing the conjugation of glutathione to a wide variety of hydrophobic and electrophilic compounds, including environmental pollutants, carcinogens, and certain therapeutic drugs. By attaching glutathione to these substances, the enzyme makes them more water-soluble, which facilitates their excretion from the body. This process is a vital defense mechanism that protects cells from oxidative stress and damage caused by reactive molecules. Because GSTP1 is expressed in many tissues throughout the body, variations in its function can have broad implications for how an individual manages chemical exposures and metabolizes specific medications that rely on this pathway for clearance.

Research Associations and Evidence

Research into rs1695 has explored its association with various health outcomes, including susceptibility to certain cancers, respiratory conditions, and responses to chemotherapy. In the context of pharmacogenomics, studies have examined whether this variant influences the toxicity or efficacy of drugs like oxaliplatin. While some studies suggest that the variant may alter enzyme activity, the clinical evidence remains moderate. Many associations reported in the literature are based on observational studies, which can sometimes show conflicting results across different populations or disease models. It is important to note that genetic associations do not imply direct causation. The impact of this variant is likely influenced by a complex interplay of other genetic factors, environmental exposures, and lifestyle choices. Consequently, the scientific community continues to evaluate the strength of these links, and it is not currently used as a definitive diagnostic tool for clinical decision-making.

Navigating Your Genetic Information

If you have received information about your rs1695 genotype, it is essential to view it within the proper context. This variant is a common feature of human genetic diversity and is not a marker for a specific disease or a guarantee of a particular drug response. Because the evidence linking this SNP to clinical outcomes is still evolving, this information should not be used to make independent health decisions or to alter any prescribed medication regimens. If you are concerned about how your genetics might influence your response to a specific medication or your risk for certain health conditions, the most appropriate step is to consult with your healthcare provider or a clinical pharmacist. They can help interpret your results in light of your full medical history, current medications, and other relevant clinical factors, ensuring that any health management strategy is safe, evidence-based, and personalized to your needs.

Frequently asked questions

Sources & further reading